Open access
278
Views
4
CrossRef citations to date
0
Altmetric
Original Research
Development of a Point-of-Care Test Based on Selenium Nanoparticles for Heart-Type Fatty Acid-Binding Proteins in Human Plasma and Blood
Lanju Wang1 Department of Blood Transfusion, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, People’s Republic of China;2 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, Henan, 475004, People’s Republic of ChinaView further author information
, Mengli Wu2 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, Henan, 475004, People’s Republic of ChinaView further author information
, Jingjing Ma2 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, Henan, 475004, People’s Republic of ChinaView further author information
, Ziwei Ma2 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, Henan, 475004, People’s Republic of China
https://orcid.org/0000-0001-9671-3520View further author information
Jiahui Liang2 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, Henan, 475004, People’s Republic of China
https://orcid.org/0000-0003-3183-3198View further author information
Ningya Tao2 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, Henan, 475004, People’s Republic of China;3 Pingyu Health School, Zhumadian, Henan, 463400, People’s Republic of ChinaView further author information
, Yangguang Ren4 Breast and Thyroid Surgery, Huaihe Hospital of Henan University, Kaifeng, Henan, 475004, People’s Republic of ChinaView further author information
, Shujun Shao1 Department of Blood Transfusion, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, People’s Republic of ChinaView further author information
, Xin Qi1 Department of Blood Transfusion, the Affiliated Tumor Hospital of Zhengzhou University, Zhengzhou, Henan, 450008, People’s Republic of ChinaCorrespondence[email protected]
View further author information
& View further author information
Zhizeng Wang2 Joint National Laboratory for Antibody Drug Engineering, Clinical Laboratory of the First Affiliated Hospital, School of Medicine, Henan University, Kaifeng, Henan, 475004, People’s Republic of ChinaCorrespondence[email protected]
https://orcid.org/0000-0003-4847-948XView further author information
Pages 1273-1284
|
Published online: 22 Mar 2022
Reprints and Permissions
Permission is granted subject to the terms of the License under which the work was published. Permission will be required if your reuse is not covered by the terms of the License.
To request a reprint or commercial or derivative permissions for this article, please click on the relevant link below.
For more information please visit our Permissions help page.
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.